CytomX Therapeutics Inc.
| NASDAQ: CTMX | Healthcare / Biotechnology / USA |
| 1.28 | -0.0600 | -4.48% | Vol 298.93K | 1Y Perf -10.07% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 1.28 | ASK | 1.34 | ||
| Open | 1.30 | Previous Close | 1.34 | ||
| Pre-Market | - | After-Market | 1.28 | ||
| - - | - -% |
| Target Price | 3.37 | Analyst Rating | Hold 3.29 | |
| Potential % | 163.28 | Finscreener Ranking | + 38.48 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | + 35.93 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★ 36.50 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 5.95 | Earnings Rating | Strong Buy | |
| Market Cap | 85.46M | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.19 | |
| Beta | 0.66 |
Today's Price Range 1.271.34 | 52W Range 1.173.02 | 5 Year PE Ratio Range -10.70-6.80 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -7.25% | ||
| 1 Month | -15.79% | ||
| 3 Months | -16.88% | ||
| 6 Months | -24.26% | ||
| 1 Year | -10.07% | ||
| 3 Years | -80.64% | ||
| 5 Years | -92.92% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -57.18 | |||
ROE last 12 Months | -158.59 | |||
ROA (5Y Avg) | -12.00 | |||
ROA last 12 Months | -36.08 | |||
ROC (5Y Avg) | -64.31 | |||
ROC last 12 Months | -108.55 | |||
Return on invested Capital Q | -41.19 | |||
Return on invested Capital Y | -21.45 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 43.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.70 | ||||
| 5.85 | ||||
| 3.64 | ||||
| 10.30 | ||||
| -1.50 | ||||
| -2.15 | ||||
| 6.26 | ||||
| 0.43 | ||||
| -8 741 400.00 | ||||
| Forward PE | -2.76 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.00 | ||||
| 2.00 | ||||
| 0.35 | ||||
| 0.67 | ||||
| - | ||||
| Leverage Ratio | 5.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -137.50 | ||||
| -134.10 | ||||
| -107.40 | ||||
| -96.67 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 52.22M | ||||
| 0.79 | ||||
| 2.62 | ||||
| 15.26 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.19 | -0.02 | 89.47 |
| Q01 2023 | -0.16 | -0.05 | 68.75 |
| Q04 2022 | -0.21 | -0.42 | -100.00 |
| Q03 2022 | -0.32 | -0.35 | -9.38 |
| Q02 2022 | -0.36 | -0.37 | -2.78 |
| Q01 2022 | -0.35 | -0.37 | -5.71 |
| Q04 2021 | -0.25 | -0.40 | -60.00 |
| Q03 2021 | -0.30 | -0.35 | -16.67 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.17 | 10.53 | Positive |
| 12/2023 QR | -0.15 | 6.25 | Positive |
| 12/2023 FY | -0.37 | 40.32 | Positive |
| 12/2024 FY | -0.50 | 37.50 | Positive |
| Next Report Date | 14th Nov 2023 |
| Estimated EPS Next Report | -0.17 |
| Estimates Count | 6 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 298.93K |
| Shares Outstanding | 66.77K |
| Shares Float | 62.16M |
| Trades Count | 954 |
| Dollar Volume | 386.82K |
| Avg. Volume | 177.05K |
| Avg. Weekly Volume | 127.92K |
| Avg. Monthly Volume | 133.79K |
| Avg. Quarterly Volume | 269.45K |
CytomX Therapeutics Inc. (NASDAQ: CTMX) stock closed at 1.28 per share at the end of the most recent trading day (a -4.48% change compared to the prior day closing price) with a volume of 298.93K shares and market capitalization of 85.46M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 146 people. CytomX Therapeutics Inc. CEO is Sean A. McCarthy.
The one-year performance of CytomX Therapeutics Inc. stock is -10.07%, while year-to-date (YTD) performance is -20%. CTMX stock has a five-year performance of -92.92%. Its 52-week range is between 1.17 and 3.02, which gives CTMX stock a 52-week price range ratio of 5.95%
CytomX Therapeutics Inc. currently has a PE ratio of -1.70, a price-to-book (PB) ratio of 5.85, a price-to-sale (PS) ratio of 3.64, a price to cashflow ratio of 10.30, a PEG ratio of -, a ROA of -36.08%, a ROC of -108.55% and a ROE of -158.59%. The company’s profit margin is -96.67%, its EBITDA margin is -134.10%, and its revenue ttm is $52.22 Million , which makes it $0.79 revenue per share.
Of the last four earnings reports from CytomX Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. CytomX Therapeutics Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for CytomX Therapeutics Inc. is Hold (3.29), with a target price of $3.37, which is +163.28% compared to the current price. The earnings rating for CytomX Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CytomX Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CytomX Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.26, ATR14 : 0.06, CCI20 : -150.75, Chaikin Money Flow : -0.15, MACD : -0.06, Money Flow Index : 11.75, ROC : -7.25, RSI : 24.80, STOCH (14,3) : 5.88, STOCH RSI : 0.00, UO : 45.56, Williams %R : -94.12), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CytomX Therapeutics Inc. in the last 12-months were: Amy C. Peterson (Sold 4 257 shares of value $8 425 ), Campoy Carlos (Sold 1 748 shares of value $3 461 ), Carlos E. Campoy (Sold 1 748 shares of value $3 459 ), Christopher Ogden (Sold 516 shares of value $1 022 ), Christopher W. Ogden (Sold 516 shares of value $1 021 ), Jeffrey B. Landau (Sold 2 954 shares of value $5 848 ), Jones Elaine (Buy at a value of $7 750), Lloyd A. Rowland (Sold 2 037 shares of value $4 031 ), Sean A. McCarthy (Sold 7 121 shares of value $13 391 )
CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.
CEO: Sean A. McCarthy
Telephone: +1 650 515-3185
Address: 151 Oyster Point Boulevard, South San Francisco 94080, CA, US
Number of employees: 146
TipRanks News for CTMX
Mon, 03 Jul 2023 10:30 GMT Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), CytomX Therapeutics (CTMX) and Bausch + Lomb Corporation (BLCO)
- TipRanks. All rights reserved.
